<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675051</url>
  </required_header>
  <id_info>
    <org_study_id>H47369-31390</org_study_id>
    <nct_id>NCT00675051</nct_id>
  </id_info>
  <brief_title>Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension</brief_title>
  <official_title>Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary hypertension is a progressive and life threatening condition. It is characterized&#xD;
      by severe remodeling of the pulmonary vessel wall, obstructive plexiform lesions, multi-focal&#xD;
      thrombosis, and enhanced vasoconstriction. All of these characteristics contribute to&#xD;
      increased pulmonary vascular resistance.&#xD;
&#xD;
      Circulating endothelial microparticles (EMPs) play an integral role in the pathogenesis and&#xD;
      perpetuation of pulmonary hypertension. Levels of EMPs are considered a reliable biological&#xD;
      parameter of endothelial injury.&#xD;
&#xD;
      We propose to assess the evolution of both circulating and pulmonary venous EMPs in patients&#xD;
      with PH. Assessments will be made before and after initiation of Endothelin-1 (ET-1) Receptor&#xD;
      blocker therapy, and correlated to their patterns with the changes in mean PAP, the 6 Minutes&#xD;
      Walking Distance test, and circulating Endothelin-1 values. Measurements of the endothelial&#xD;
      microparticle circulating levels (assessed by flow cytometry methods) will be made before, 1&#xD;
      month and 3 months after initiation of therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Precapillary Pulmonary Hypertension&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient's + 18 years with suspected pre-capillary pulmonary hypertension&#xD;
&#xD;
          -  Prescribed Endothelial - 1 receptor blocker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently taking endothelium-active vasodilator therapy.&#xD;
&#xD;
          -  Hemoglobin and / or hematocrit level blood the lower normal limit.&#xD;
&#xD;
          -  Left ventricle dysfunction (LVEF &lt;50%)&#xD;
&#xD;
          -  LV end-diastolic pressure &gt; 15 mmHg)&#xD;
&#xD;
          -  Recent history (&lt;3 months) of pulmonary embolism&#xD;
&#xD;
          -  Liver failure or abnormal liver function tests; aortic or mitral regurgitation or&#xD;
             stenosis&#xD;
&#xD;
          -  Current medication with endothelin-1 receptor antagonist, prostacyclin analogues or&#xD;
             type 5 phosphodiesterase inhibitors.&#xD;
&#xD;
          -  Subjects with conditions known to be associated with an increase in circulating&#xD;
             endothelial microparticle numers, such as chronic renal failure (Creatinine Clearance&#xD;
             &lt; 50 ml/min/m2) acute coronary syndromes and uncontrolled system hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Yerem Yeghiazarians</investigator_full_name>
    <investigator_title>Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>To determine if there is a trans-pulmonary gradient in the levels of EMPs in patients with PH</keyword>
  <keyword>To determine if the EMPs measured at the pulmonary capillary wedge position correlates even more strongly with the severity of PH than the circulating levels</keyword>
  <keyword>To determine if PH therapy with ET-1 receptor blocker will modify EMPs levels</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

